Compare · OMIC vs RVTY
OMIC vs RVTY
Side-by-side comparison of Singular Genomics Systems Inc. (OMIC) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OMIC and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- RVTY carries a market cap of $17.24B.
- RVTY has hit the wire 8 times in the past 4 weeks while OMIC has been quiet.
- RVTY has more recent analyst coverage (24 ratings vs 5 for OMIC).
- Company
- Singular Genomics Systems Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- -
- $17.24B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 8
- Recent ratings
- 5
- 24
Singular Genomics Systems Inc.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
Latest OMIC
- Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)
- Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.
- Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Glezer Eli N. returned 155,583 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operating Officer Ghai Jyotsna returned 3,283 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Ryan Jason
- Director Pellini Michael J returned 351,222 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Mardis Elaine R
Latest RVTY
- vVardis Raises $175 Million Ahead of NYSE IPO: NYSE Content Update
- Revvity Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Revvity to Showcase Strategy for Powering Scientific Intelligence at 2026 Investor Day
- SEC Form 10-Q filed by Revvity Inc.
- Revvity upgraded by CFRA
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Third Quarter of 2026
- Revvity Board Declares Quarterly Dividend
- Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows
- Revvity to Present at Upcoming Investor Conferences